GENE ONLINE|News &
NS-229, a JAK1 Inhibitor, Under Investigation as Potential Treatment for EGPA Nerve Cell Inflammation
A potential treatment for eosinophilic granulomatosis with polyangiitis (EGPA) is under investigation. The drug, called NS-229, functions as a Janus kinase 1 (JAK1) inhibitor. EGPA is a rare autoimmune condition characterized by inflammation of nerve cells. This inflammation can lead to severe allergic and asthmatic symptoms. NS-229 aims to address the condition by inhibiting JAK1.
Newsflash | Powered by GeneOnline AI
Date: April 25, 2025
Author
LATEST
A Look at Taiwan-German Collaborative Solutions in Precision Medicine, Drug Development, and Medical Tech
2025-05-21
ACOG Updates Pain Management Guidelines for IUD Insertions as Novavax Vaccine Gains Approval
2025-05-20
UnitedHealth Group Stock Drops Amid Rising Medicare Advantage Costs and Regulatory Debates
2025-05-20
